[1] WANG F,XU RH,HAN B,et al.High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers[J].Cancer,2007,109(7):1360.
[2] CHEN MH,HSIAO LT,CHIOU TJ,et al.High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin's lymphoma[J].Ann Hematol,2008,87(6):475.
[3] 刘卫平,郑文.王小沛,等.405例非霍奇金淋巴瘤患者乙型肝炎病毒感染率分析[J].中华血液学杂志,2011,32(8):521.
[4] Liver EAFTSOT.Corrigendum to:"EASL clinical practice guidelines:Management of chronic hepatitis B virus infection"[J].J Hepatol,2012,57(1):167.
[5] YEO W,CHAN PK,ZHONG S,et al.Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemo-therapy:aprospective study of 626 patients with identification of risk factors[J].J Med Virol,2000,629(3):209.
[6] 郭海鹰,王小渝.乙肝病毒感染的恶性淋巴瘤患者化疗后肝功能衰竭死亡3例及文献复习[J].华西医学,2008,23(2):345.
[7] YEO W,HUI EP,CHAN AT,et al.Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine[J].Am J Clin Oncol,2005,28(4):379.
[8] CHOU CK,WANG LH,LIN HM,et al.Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells[J].Hepatology,1992,16(1):13.
[9] CHENG AL,HSIUNG CA,SU IJ,et al.Steroid-free chemotherapy decreases risk of hepatitis B virus(HBV) reactivation in HBV-carriers with lymphoma[J].Hepatology,2003,37(6):1320.
[10] 李军民.《淋巴瘤合并HBV感染患者管理中国专家共识》解读[J].中华血液学杂志,2014,35(4):371.
[11] 黄晶,陈小苹,陈学福,等.拉米夫定及恩替卡韦预防和治疗非霍奇金淋巴瘤相关性HBV再激活的疗效对比[J].实用医学杂志,2011,27(12):2225.
[12] 倪传斌,龙波.拉米夫定及恩替卡韦预防和治疗非霍奇金淋巴瘤相关性HBV再激活的疗效对比[J].临床肝胆病杂志,2014,30(4):363.
[13] 谭英,吴惠芳,邹萌丽,等.拉米夫定及恩替卡韦治疗非何杰金淋巴瘤相关性HBV再激活的对照研究[J].江西医药,2014,49(9):854.